RKRafal M. Kaminski

Rafal M. Kaminski

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rafal M. Kaminski has a total of 106 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A systems-level framework for drug discovery identifies Csf1R as an anti-epileptic drug target

    by Prashant K. Srivastava, Jonathan van Eyll, Patrice Godard, Manuela Mazzuferi, Andree Delahaye-Duriez, Juliette Van Steenwinckel, Pierre Gressens, Benedicte Danis, Catherine Vandenplas, Patrik Foerch, et al.

    The identification of drug targets is highly challenging, particularly for diseases of the brain. To address this problem, we developed and experimentally validated a general computational framework for drug target discovery that combines gene regulatory information with causal reasoning (“Causal Reasoning Analytical Framework for Target discovery”—CRAFT). Using a systems genetics approach and starting from gene expression data from the target tissue, CRAFT provides a predictive framework for identifying cell membrane receptors with a direction-specified influence over disease-related gene expression profiles. As proof of concept, we applied CRAFT to epilepsy and predicted the tyrosine kinase receptor Csf1R as a potential therapeutic target. The predicted effect of Csf1R blockade in attenuating epilepsy seizures was validated in three pre-clinical models of epilepsy. These results highlight CRAFT as a systems-level framework for target discovery and suggest Csf1R blockade as a novel therapeutic strategy in epilepsy. CRAFT is applicable to disease settings other than epilepsy.


  • Open Access

    Inhibition of glutamate decarboxylase (GAD) by ethyl ketopentenoate (EKP) induces treatment-resistant epileptic seizures in zebrafish

    by Yifan Zhang, Michiel Vanmeert, Aleksandra Siekierska, Annelii Ny, Jubi John, Geert Callewaert, Eveline Lescrinier, Wim Dehaen, Peter A. M. de Witte, Rafal M. Kaminski

    Epilepsy is a chronic brain disorder characterized by recurrent seizures due to abnormal, excessive and synchronous neuronal activities in the brain. It affects approximately 65 million people worldwide, one third of which are still estimated to suffer from refractory seizures. Glutamic acid decarboxylase (GAD) that converts glutamate into GABA is a key enzyme in the dynamic regulation of neural network excitability. Importantly, clinical evidence shows that lowered GAD activity is associated with several forms of epilepsy which are often treatment resistant. In the present study, we synthetized and explored the possibility of using ethyl ketopentenoate (EKP), a lipid-permeable GAD-inhibitor, to induce refractory seizures in zebrafish larvae. Our results demonstrate that EKP evoked robust convulsive locomotor activities, excessive epileptiform discharges and upregulatedc-fosexpression in zebrafish. Moreover, transgenic animals in which neuronal cells express apoaequorin, a Ca2+-sensitive bioluminescent photoprotein, displayed large luminescence signals indicating strong EKP-induced neuronal activation. Molecular docking data indicated that this proconvulsant activity resulted from the direct inhibition of both gad67 and gad65. Limited protective efficacy of tested anti-seizure drugs (ASDs) demonstrated a high level of treatment resistance of EKP-induced seizures. We conclude that the EKP zebrafish model can serve as a high-throughput platform for novel ASDs discovery.


  • Open Access

    Neuroinflammatory targets and treatments for epilepsy validated in experimental models

    by Eleonora Aronica, Sebastian Bauer, Yuri Bozzi, Matteo Caleo, Raymond Dingledine, Jan A. Gorter, David C. Henshall, Daniela Kaufer, Sookyong Koh, Wolfgang Löscher, et al.

    Summary: A large body of evidence that has accumulated over the past decade strongly supports the role of inflammation in the pathophysiology of human epilepsy. Specific inflammatory molecules and pathways have been identified that influence various pathologic outcomes in different experimental models of epilepsy. Most importantly, the same inflammatory pathways have also been found in surgically resected brain tissue from patients with treatment‐resistant epilepsy. New antiseizure therapies may be derived from these novel potential targets. An essential and crucial question is whether targeting these molecules and pathways may result in anti‐ictogenesis, antiepileptogenesis, and/or disease‐modification effects. Therefore, preclinical testing in models mimicking relevant aspects of epileptogenesis is needed to guide integrated experimental and clinical trial designs. We discuss the most recent preclinical proof‐of‐concept studies validating a number of therapeutic approaches against inflammatory mechanisms in animal models that could represent novel avenues for drug development in epilepsy. Finally, we suggest future directions to accelerate preclinical to clinical translation of these recent discoveries.


  • Open Access

    A Systems-Level Framework for Drug Discovery Identifies Csf1R As A Novel Anti-Epileptic Drug Target

    by Prashant K. Srivastava, Jonathan van Eyll, Patrice Godard, Manuela Mazzuferi, Benedicte Danis, Catherine Vandenplas, Patrik Foerch, Karine Leclercq, Georges Mairet-Coello, Frederic Vanclef, et al.

    The identification of mechanistically novel drug targets is highly challenging, particularly for diseases of the central nervous system. To address this problem we developed and experimentally validated a new computational approach to drug target identification that combines gene-regulatory information with a causal reasoning framework (“causal reasoning analytical framework for target discovery” – CRAFT). Starting from gene expression data, CRAFT provides a predictive functional genomics framework for identifying membrane receptors with a direction-specified influence over network expression. As proof-of-concept we applied CRAFT to epilepsy, and predicted the tyrosine kinase receptor Csf1R as a novel therapeutic target for epilepsy. The predicted therapeutic effect of Csf1R blockade was validated in two pre-clinical models of epilepsy using a small molecule inhibitor of Csf1R. These results suggest Csf1R blockade as a novel therapeutic strategy in epilepsy, and highlight CRAFT as a systems-level framework for predicting mechanistically new drugs and targets. CRAFT is applicable to disease settings other than epilepsy.


  • Resveratrol lacks protective activity against acute seizures in mouse models

    by Francesca Tomaciello, Karine Leclercq, Rafal M. Kaminski


  • Open Access

    Differential expression of miR-184 in temporal lobe epilepsy patients with and without hippocampal sclerosis – Influence on microglial function

    by Bénédicte Danis, Marijke van Rikxoort, Anita Kretschmann, Jiong Zhang, Patrice Godard, Lidija Andonovic, Franziska Siegel, Pitt Niehusmann, Etienne Hanon, Daniel Delev, et al.

    Epilepsy is one of the most common neurological disorders characterized by recurrent seizures due to neuronal hyperexcitability. Here we compared miRNA expression patterns in mesial temporal lobe epilepsy with and without hippocampal sclerosis (mTLE + HS and mTLE −HS) to investigate the regulatory mechanisms differentiating both patient groups. Whole genome miRNA sequencing in surgically resected hippocampi did not reveal obvious differences in expression profiles between the two groups of patients. However, one microRNA (miR-184) was significantly dysregulated, which was confirmed by qPCR. We observed that overexpression of miR-184 inhibited cytokine release after LPS stimulation in primary microglial cells, while it did not affect the viability of murine primary neurons and primary astrocytes. Pathway analysis revealed that miR-184 is potentially involved in the regulation of inflammatory signal transduction and apoptosis. Dysregulation of some the potential miR-184 target genes was confirmed by qPCR and 3′UTR luciferase reporter assay. The reduced expression of miR-184 observed in patients with mTLE + HS together with its anti-inflammatory effects indicate that miR-184 might be involved in the modulation of inflammatory processes associated with hippocampal sclerosis which warrants further studies elucidating the role of miR-184 in the pathophysiology of mTLE.


  • Open Access

    Cross-species pharmacological characterization of the allylglycine seizure model in mice and larval zebrafish

    by Karine Leclercq, Tatiana Afrikanova, Melanie Langlois, An De Prins, Olivia E. Buenafe, Chiara C. Rospo, Ann Van Eeckhaut, Peter A.M. de Witte, Alexander D. Crawford, Ilse Smolders, et al.


  • Genetic background of mice strongly influences treatment resistance in the 6 Hz seizure model

    by Karine Leclercq, Rafal M. Kaminski

    Summary: Objective: The 6 Hz model of focal seizures has been increasingly used to identify anticonvulsant compounds with potential activity against therapy‐resistant epilepsy, but the protective response to anticonvulsants in this model could be dependent on experimental conditions and selection of mouse strains.Methods: Seizure thresholds in the 6 Hz model were compared inCF‐1,NMRI, andC57Bl/6Jmale mice with two different electrical stimulators (Ugo Basile 5780 and Grass S48). Dose–response curves for phenytoin and levetiracetam were generated in the three strains at 32 and 44 mA current intensities using both devices. Plasma and brain exposure to the two drugs were measured in all three strains.Results: CF‐1 mice had the lowest seizure threshold and responded to phenytoin at 32 mA stimulation intensity, but not at 44 mA.NMRIandC57Bl/6Jmice had nearly identical threshold values, butNMRImice responded well to phenytoin at 32 mA and showed limited responsiveness to this drug at 44 mA, whereasC57Bl/6Jmice were nearly completely resistant to phenytoin. Furthermore, levetiracetam showed limited efficacy and low potency inCF‐1 andC57Bl/6Jmice, particularly at 44 mA, whereas inNMRImice the drug showed much higher potency in all experimental conditions. No obvious difference in the pharmacokinetics of both phenytoin and levetiracetam was detected between the mouse strains that would have explained these unexpected variations in potency. We have also found that the protective effects of both drugs may be influenced by the device type.Significance: Collectively these observations clearly indicate that treatment resistance of 6 Hz seizures should be interpreted with strain and experimental conditions in mind. Furthermore, it is important to note that strain differences, much like human genetic differences, may explain why some mice and patients respond to a given treatment and others do not.